US 12,059,456 B2
Methods of using C1 esterase inhibitor for improving early onset and long-term function of kidney transplants from grafts associated with delayed graft function
Stanley Jordan, Manhattan Beach, CA (US); Jua Choi, Porter Ranch, CA (US); and Ashley Vo, Northridge, CA (US)
Assigned to Cedars-Sinai Medical Center, Los Angeles, CA (US)
Appl. No. 16/646,539
Filed by Cedars-Sinai Medical Center, Los Angeles, CA (US)
PCT Filed Sep. 14, 2018, PCT No. PCT/US2018/051045
§ 371(c)(1), (2) Date Mar. 11, 2020,
PCT Pub. No. WO2019/055763, PCT Pub. Date Mar. 21, 2019.
Claims priority of provisional application 62/559,312, filed on Sep. 15, 2017.
Prior Publication US 2020/0276283 A1, Sep. 3, 2020
Int. Cl. A61K 38/57 (2006.01); A61K 9/00 (2006.01)
CPC A61K 38/57 (2013.01) [A61K 9/0019 (2013.01)] 7 Claims
 
1. A method for reducing the likelihood of delayed kidney allograft function and improving allograft kidney function at about one year following transplantation in a human subject, the method comprising administering to the subject a therapeutically effective amount of one or more C1 esterase inhibitors only at times of (i) the day of the transplantation but prior to reperfusion of the allograft kidney in the subject and (ii) about 24 hours after the transplantation,
wherein the therapeutically effective amount of the one or more C1 esterase inhibitors combined, each time, is about 50 units/kg of the subject, wherein the therapeutically effective amount is effective for improving the estimated glomerular filtration rate (eGFR) at about one year post-transplantation to be higher than the subject's eGFR within one week following the transplantation and
wherein the allograft kidney was obtained from an extended criteria donor (ECD) or from a donor after cardiac death (DCD).